TITLE

Doxazosin plus finasteride reduced clinical progression of benign prostatic hyperplasia more than either drug used alone

AUTHOR(S)
Hoffman, Richard
PUB. DATE
July 2004
SOURCE
ACP Journal Club;Jul/Aug2004, Vol. 141 Issue 1, p20
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Doxazosin plus finasteride reduced clinical progression of benign prostatic hyperplasia more than either drug used alone. In men with benign prostatic hyperplasia, long-term doxazosin plus finasteride combination therapy reduced the risk for overall clinical progression of benign prostatic hyperplasia more than either drug used alone. Both drugs used alone were more effective than placebo. Combination therapy also reduced the risk for clinical progression more than either drug alone. Both drugs used alone were more effective than placebo. Combination therapy also reduced the risk for clinical progression more than either drug alone.
ACCESSION #
13916265

 

Related Articles

  • Benign prostatic hyperplasia.  // Current Medical Literature: Urology;2003, Vol. 9 Issue 2, p37 

    Presents citations and clinicians' notes concerning benign prostatic hyperplasia. Effectiveness of doxazosin and finasteride for treating benign prostatic hyperplasia; Evolution of detrusor overactivity in patients with bladder outlet obstruction; Transurethral electrovaporization of the prostate.

  • CITATIONS AND CLINICIANS' NOTES: BENIGN PROSTATIC HYPERPLASIA.  // Current Medical Literature: Urology;2004, Vol. 10 Issue 2, p38 

    Presents abstracts of articles concerning benign prostatic hyperplasia, published in the June 2004 issue of the periodical "Urology". Long-term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia; Sustained decrease in incidence of...

  • Advances in the medical management of benign prostatic hyperplasia. Jewett, Michael A. S.; Klotz, Laurence H. // CMAJ: Canadian Medical Association Journal;6/19/2007, Vol. 176 Issue 13, p1850 

    The article discusses the advancement in the medical management of benign prostatic hyperplasia (BPH) in men. The results from the Medical Therapy of Prostatic Symptoms found that the use of doxazosin in combination with finasteride slowed down the clinical progression of BPH, particularly in...

  • A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Rigatti, P.; Brausi, M.; Scarpa, R. M.; Porru, D.; Schumacher, H.; Rizzi, C. A. // Prostate Cancer & Prostatic Diseases;2003, Vol. 6 Issue 4, p315 

    In this multicentre, double-blind study, patients with LUTS/BPH were randomised to 26 weeks with finasteride 5?mg once daily (n=204) or tamsulosin 0.4?mg once daily (n=199). Double-blind treatment was continued for another 26 weeks (total treatment duration: 1?y). The primary efficacy parameter...

  • The therapeutic effect of clinical trials: understanding placebo response rates in clinical trials -- A secondary analysis. Walach, Harald; Sadaghiani, Catarina; Dehm, Cornelia; Bierman, Dick // BMC Medical Research Methodology;2005, Vol. 5, p26 

    Background and purpose: Placebo response rates in clinical trials vary considerably and are observed frequently. For new drugs it can be difficult to prove effectiveness superior to placebo. It is unclear what contributes to improvement in the placebo groups. We wanted to clarify, what elements...

  • Baseline characteristics and patient reported outcome data of patients prescribed etanercept: web-based and telephone evaluation. Wade, Alan G.; Crawford, Gordon M.; Pumford, Neil; Koscielny, Volker; Maycock, Susan; McConnachie, Alex // BMC Medical Research Methodology;2011, Vol. 11 Issue 1, p91 

    Background: The anti-TNF inhibitor, etanercept is administered as a once or twice weekly subcutaneous injection for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis (JIA). Limited data from the patients' perspective...

  • QRXPHARMA BEGINS PHASE III CLINICAL TRIAL FOR PAIN THERAPY.  // Worldwide Biotech;Jan2008, Vol. 20 Issue 1, p1 

    The article reports on the Phase III clinical trial conducted by QRxPharma for its lead product candidate Q8003IR, an immediate release dual-opioid pain therapy. The trial involved a double-blind, placebo-controlled study that aims to compare the efficacy and safety of four different dosage...

  • A New Approach to the Treatment of Uncomplicated Cystitis: Results of a Randomized Placebo-Controlled Clinical Trial. Salvatorelli, Nicola; García-Larrosa, alejandro; allegrini, alessandro; Pavone, Daniele // Urologia Internationalis;Oct2016, Vol. 97 Issue 3, p347 

    Objective: To assess the efficacy and safety of a new medical device (MD; a capsule whose main component is a crosslinked protein) in the prevention of uncomplicated cystitis recurrences. Methods: Adult women with acute cystitis symptoms and a ciprofloxacin-susceptible isolate in urine culture...

  • Toviaz Top-Line Primary Endpoint Results Positive In Overactive Bladder Study Of Nocturnal Urinary Urgency.  // Biomedical Market Newsletter;11/16/2011, Vol. 21, p67 

    The article reports on the results of the Toviaz, fesoterodine fumarate, Study A0221048 by Pfizer Inc. The study aims to determine the effectiveness and safety of a flexible dose regimen for patients with overactive bladder including nocturnal urinary urgency. It also reveals that treatment with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics